Abstract 6972: Programmed death-ligand 1 (PD-L1) upregulates c-MET phosphorylation via protein tyrosine phosphatase and contributes to the development of <i>MET</i> amplification in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer
Derek De-Rui Huang(National Taiwan University Hospital), James Chih‐Hsin Yang(National Taiwan University Hospital), Bin-Chi Liao(National Taiwan University Hospital), Chia‐Chi Hsu(National Taiwan University Hospital), Wei‐Hsun Hsu(Royal Prince Alfred Hospital)
Cited by 0
Related Papers
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k